President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s resignation has positioned the FDA deputy commissioner for food as the clear frontrunner in trader assessments for the permanent role. Diamantas assumed acting duties in mid-May 2026 after serving in senior FDA food-policy positions and has received public White House support for advancing administration priorities on food safety and regulatory reform. Other names under active consideration, including former commissioner Stephen Hahn and former acting commissioner Brett Giroir, register lower probabilities consistent with their more limited recent involvement in day-to-day agency operations. The market also prices a meaningful chance of no formal announcement before year-end, reflecting the ongoing search process and typical timelines for Senate-confirmed appointments.
基于Polymarket数据的AI实验性摘要。这不是交易建议,也不影响该市场的结算方式。 · 更新于Kyle Diamantas 49%
No announcement by December 31 13.5%
Stephen Hahn 4%
Brett Giroir 3.4%
Kyle Diamantas
49%
Stephen Hahn
4%
Brett Giroir
3%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
14%
Kyle Diamantas 49%
No announcement by December 31 13.5%
Stephen Hahn 4%
Brett Giroir 3.4%
Kyle Diamantas
49%
Stephen Hahn
4%
Brett Giroir
3%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
14%
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
市场开放时间: May 12, 2026, 7:59 PM ET
Resolver
0x69c47De9D...An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Resolver
0x69c47De9D...President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s resignation has positioned the FDA deputy commissioner for food as the clear frontrunner in trader assessments for the permanent role. Diamantas assumed acting duties in mid-May 2026 after serving in senior FDA food-policy positions and has received public White House support for advancing administration priorities on food safety and regulatory reform. Other names under active consideration, including former commissioner Stephen Hahn and former acting commissioner Brett Giroir, register lower probabilities consistent with their more limited recent involvement in day-to-day agency operations. The market also prices a meaningful chance of no formal announcement before year-end, reflecting the ongoing search process and typical timelines for Senate-confirmed appointments.
基于Polymarket数据的AI实验性摘要。这不是交易建议,也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题